设为首页收藏本站
开启辅助访问 切换到窄版

 找回密码
 To register

QQ登录

只需一步，快速开始

扫一扫，访问微社区

  • ALL
  • Journals
  • Books

派博传思国际中心 »期刊书目

› Journal of SCIE
› IMMUNOLOGY(免疫学)

1234下一页
返回列表

SCIE期刊Endocrine Metabolic & Immune Disorders-Drug Targets 2024/2025影响因子:2.108 (ENDOCR METAB IMMUNE) (1871-5303). (IMMUN

[复制链接]
查看: 37599|回复: 35
发表于 2025-3-21 19:35:21 | 显示全部楼层 |阅读模式
期刊全称Endocrine Metabolic & Immune Disorders-Drug Targets
期刊简称ENDOCR METAB IMMUNE
影响因子20242.108
视频videohttp://file.papertrans.cn/9/8344/8344.mp4
ISSN1871-5303
eISSN2212-3873
出版商BENTHAM SCIENCE PUBL LTD
发行地址EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, SHARJAH, U ARAB EMIRATES, 1200 BR
学科分类1.Science Citation Index Expanded (SCIE)--Endocrinology & Metabolism | Immunology | Pharmacology & Pharmacy; 2.BIOSIS Previews_BIOSIS Citation Index--Endocrinology & Metabolism | Immunology | Pharmacology & Pharmacy; 3.BIOSIS Reviews Reports And Meetings--Endocrinology & Metabolism | Immunology | Pharmacology & Pharmacy; 4.Essential Science Indicators--Pharmacology & Toxicology;
出版语言English
The information of publication is updating

SCIE(SCI)期刊Endocrine Metabolic & Immune Disorders-Drug Targets(20 21 REV HIST)影响因子


SCIE(SCI)期刊Endocrine Metabolic & Immune Disorders-Drug Targets(ENDOCR METAB IMMUNE)影响因子@(免疫学)学科排名


SCIE(SCI)期刊Endocrine Metabolic & Immune Disorders-Drug Targets(20 21 REV HIST)总引论文


SCIE(SCI)期刊Endocrine Metabolic & Immune Disorders-Drug Targets(ENDOCR METAB IMMUNE)总引论文@(免疫学)学科排名


SCIE(SCI)期刊Endocrine Metabolic & Immune Disorders-Drug Targets(20 21 REV HIST)影响因子


SCIE(SCI)期刊Endocrine Metabolic & Immune Disorders-Drug Targets(ENDOCR METAB IMMUNE)总引频次@(免疫学)学科排名


SCIE(SCI)期刊Endocrine Metabolic & Immune Disorders-Drug Targets(20 21 REV HIST)即时影响因子


SCIE(SCI)期刊Endocrine Metabolic & Immune Disorders-Drug Targets(ENDOCR METAB IMMUNE)即时影响因子@(免疫学)学科排名


SCIE(SCI)期刊Endocrine Metabolic & Immune Disorders-Drug Targets(20 21 REV HIST)五年累积影响因子


SCIE(SCI)期刊Endocrine Metabolic & Immune Disorders-Drug Targets(ENDOCR METAB IMMUNE)五年累积影响因子@(免疫学)学科排名


单选投票, 共有 1 人参与投票
1.jpg
 

1票 100.00%

Perfect with Aesthetics
2.jpg
 

0票 0.00%

Better Implies Difficulty
3.jpg
 

0票 0.00%

Good and Satisfactory
4.jpg
 

0票 0.00%

Adverse Performance
5.jpg
 

0票 0.00%

Disdainful Garbage
您所在的用户组没有投票权限
GERM
回复

举报

发表于 2025-3-21 23:23:03 | 显示全部楼层
Submitted on: 03 July 2015. Revised on: 20 October 2015. Accepted on: 15 December 2015. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets
Digest
回复

举报

发表于 2025-3-22 01:52:01 | 显示全部楼层
Submitted on: 19 May 2008. Revised on: 04 August 2008. Accepted on: 25 September 2008. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets
scrutiny
回复

举报

发表于 2025-3-22 07:30:46 | 显示全部楼层
Submitted on: 07 July 2012. Revised on: 27 July 2012. Accepted on: 02 September 2012. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets
失眠症
回复

举报

发表于 2025-3-22 10:54:28 | 显示全部楼层
Submitted on: 10 September 2020. Revised on: 04 October 2020. Accepted on: 14 October 2020. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets
平项山
回复

举报

发表于 2025-3-22 14:27:29 | 显示全部楼层
Submitted on: 10 February 2023. Revised on: 16 May 2023. Accepted on: 12 June 2023. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets
Inscrutable
回复

举报

发表于 2025-3-22 19:09:43 | 显示全部楼层
Dysarthria
回复

举报

发表于 2025-3-22 21:18:56 | 显示全部楼层
Hemiplegia
回复

举报

发表于 2025-3-23 05:23:41 | 显示全部楼层
Submitted on: 17 May 2002. Revised on: 01 August 2002. Accepted on: 13 August 2002. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets
catagen
回复

举报

发表于 2025-3-23 06:41:34 | 显示全部楼层
Submitted on: 24 February 2004. Revised on: 18 May 2004. Accepted on: 05 July 2004. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets
1分开
回复

举报

下一页 »
1234下一页
返回列表
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 吾爱论文网 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
QQ|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-11-4 10:57
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表